What's new

Clinical human trials begin for COVID-19 vaccine in China

Clover Biopharmaceuticals @CloverBiopharma

Clover's #COVID19 vaccine candidate met the primary and secondary efficacy endpoints in SPECTRA, our global Phase 2/3 clinical trial and demonstrated 79% efficacy against COVID-19 of any severity caused by the globally dominant #Delta strain. Learn more: https://lnkd.in/grZwPfeF

Image
11:29 PM · Sep 22, 2021
We are pleased to announce new positive clinical data evaluating our #COVID19 #vaccine candidate, SCB-2019 (CpG 1018/Alum).
Follow-up efficacy data showed SCB-2019 (CpG 1018/Alum) demonstrated durable high protection in individuals at five months after second dose of SCB-2019 (CpG 1018/Alum).
Preliminary data in both homologous and heterologous booster settings showed SCB-2019 (CpG 1018/Alum) induced strong immune responses and broad neutralization against all variants of concern, including #Omicron, when administered as a booster dose.
 
. . . .
We are pleased to announce that the NMPA of China granted approval for the clinical trial application of our COVID-19 #mRNA #vaccine,which induces high-titer neutralizing antibody levels against multiple #VOC identified by the WHO, including the #Omicron.

CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PR Newswire APAC https://enmobile.prnasia.com/releases/apac/cansinobio-s-covid-19-mrna-vaccine-receives-approval-of-clinical-trial-application-in-china-356961.shtml

Study showed that our #mRNA vaccine can induce neutralizing antibodies with greater cross-reactivity against global #VOCs and provide stronger protection against infections.
 
. .
The COVID-19 drug treatment Proxalutamide from Kintor that was doubted to be "too good to be true" after its initial announcement in pre-print, has announced result from phase three clinical trial. And it appear to be good.

Kintor Pharma’s Proxalutamide Demonstrated Reduction in Hospitalization/Mortality for Patients with Mild to Moderate COVID-19 in Phase III MRCT Study
  • Proxalutamide demonstrates a significant reduction in hospitalization/death rate with a protection rate reaching 100% for patients treated more than seven days (p <0.02).
  • Proxalutamide reduced risk of hospitalization or death especially in those with high-risk factors.
  • Proxalutamide demonstrates significant reduction in COVID-19 viral load and improved coronavirus-related symptoms.
  • The Phase III multi-regional clinical trial (MRCT) enrolled 99% of patients in multiple centers accross the United States.
Shares of China’s Kintor Pharmaceutical [HKG: 9939] opened up 200% today after the Suzhou-based drugmaker said its oral treatment for #COVID19, Proxalutamide, was proved to effectively reduce hospital admissions and mortality in the phase three trials.
 
Last edited:
.

Traditional Chinese medicines beneficial in treatment of COVID-19: WHO​

Source: Xinhua Editor: huaxia 2022-04-06 19:15:12

GENEVA, April 6 (Xinhua) -- Traditional Chinese medicines (TCMs) are beneficial in the treatment of COVID-19, particularly mild-to-moderate cases, according to a new report released by the World Health Organization (WHO).

It also encourages member states to consider the potential use of TCM for the management of COVID-19 in the context of their healthcare systems and regulatory frameworks.

The report came in late March after a WHO Expert Meeting on Evaluation of TCMs in the Treatment of COVID-19 was held virtually from Feb. 28 to March 2.

The meeting gathered 21 international experts from the six WHO regions to consider three reports, including on clinical service, research and evidence-based evaluation provided by national expert groups in China.

According to the WHO report, there are also promising data to suggest that TCM is beneficial in reducing the risk of progression from mild-to-moderate cases to severe COVID-19.

For mild-to-moderate cases, the report noted there is encouraging evidence that the studied TCMs, when administered as add-on interventions to conventional treatment, may shorten the time for viral clearance, resolution of clinical symptoms and length of hospital stay when compared to conventional treatment alone.

Meanwhile, experts hold that the studied TCM interventions, given in addition to conventional treatment, were well tolerated and have a safety profile that is comparable to that of conventional treatment alone.

There is also encouraging evidence that early application of TCM may result in better clinical outcomes for patients with mild-to-moderate COVID-19, the report added.

Based on the findings, the report recommends that the WHO share the outcomes of the meeting with member states in a timely manner, given the evolving nature of COVID-19 globally.

For member states, in addition to considering the potential use of TCMs, it is also recommended that they share experiences and lessons, particularly those actively acquired through this organized research program in TCM and clinical experience from China.

Participants of the expert meeting expressed their appreciation of the significant investment and effort made by the Chinese government and its researchers to advance knowledge and to develop therapeutics for the management of COVID-19 from the outset of the current pandemic.

They added that further research is warranted on TCM for the treatment of COVID-19 since the progress to date lays a strong foundation for international collaboration and cooperation that will potentially benefit human health globally through more effective and appropriate application of TCM for COVID-19.
 
. . . .
Last edited:
.
The 2nd generation recombinant protein vaccine for #COVID19 developed by Sinopharm, which is protective against various mutations, has received approval from China’s National Medical Products Administration to enter clinical trials.
Omicron came too suddenly and China didn't have enough time to react, the old strategy for delta and the earlier versions is not practical anymore. After this will be more stringent testing etc. China is tweaking the dynamic zero strategy to be a balance between economy and society. Covid is not over guys, today US has 105k infections, mild when only 1900 dead but in 35 days only 500+ Chinese died. The death on US for one day is 3x the death of Chinese in 35 days. Thats the truth CNN will never report.
 
. . .
Back
Top Bottom